Delivery Order SPE2DB20D3103-SPE2DB23FP4Z5

Award Date 8/25/23
Potential Completion Date 8/28/23
Potential Value $16K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract has an award value of $1,221.51 and is for the delivery of 4567199444 - OSELTAMIVIR PHOS 75 MG CAPSULE UD 10S. It is a firm fixed-price delivery order contract with a completion date of February 7, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,742.98 firm fixed-price delivery order is for the supply of 4,566,975,174 units of OSELTAMIVIR PHOS 75 MG CAPSULE UD 10S, with a completion date of January 21, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OSELTAMIVIR PHOS 75 MG CAPSULE UD 10S medical supplies. The award, valued at $1,494.51, was made by the Defense Logistics Agency (DLA) through a Delivery Order contract with a Firm Fixed Price pricing type. The contract has an ultimate completion date of November 3, 2023. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen...
This is a $1,390.66 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of 4567173154 - OSELTAMIVIR PHOS 75 MG CAPSULE UD 10S, with a period of performance ending on February 6, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a comprehensive range of...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide OSELTAMIVIR PHOS 75 MG CAPSULE UD 10S medical supplies. The contract, valued at $1,884.96, is a delivery order with a firm fixed price and an ultimate completion date of January 18, 2024. AmerisourceBergen, a for-profit organization, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth $999,999,999,...
This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,966.60, is for the delivery of 4567075558 - OSELTAMIVIR PHOS 75 MG CAPSULE 10S. It is a firm-fixed-price delivery order contract with a period of performance through January 29, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a...
This is a federal contract award by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,347.31, is for the delivery of 4567640023 - OSELTAMIVIR PHOS 75 MG CAPSULE UD 10S. It is a Firm Fixed Price Delivery Order contract with a period of performance through March 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the delivery of 4563855693 OSELTAMIVIR PHOS 75 MG CAPSULE UD 10S. The $3,117.65 firm fixed price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,041.06 firm fixed-price delivery order is for the supply of 4567341626 Oseltamivir Phosphate 75 mg capsules. The contract has an ultimate completion date of February 24, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,333.19 firm fixed-price contract is for the supply of OSELTAMIVIR PHOS 75 MG CAPSULE UD 10S, a medication, with a performance period through April 4, 2025. This order is part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB23FP4Z5
    Delivery Order

This contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of OSELTAMIVIR PHOS 75 MG CAPSULE UD 10S to the Defense Logistics Agency (DLA). The $16,028.80 firm-fixed-price delivery order has an ultimate completion date of August 28, 2023. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024 for similar medical products and prescription drugs.

Generated 2/27/25, 12:11 PM